Duality Biotherapeutics Inc. Initiates Phase 1/2 Clinical Trial of Innovative EGFR/HER3 Bispecific Antibody-Drug Conjugate for Advanced Solid Tumors

Reuters07-09

Duality Biotherapeutics Inc. Initiates Phase 1/2 Clinical Trial of Innovative EGFR/HER3 Bispecific Antibody-Drug Conjugate for Advanced Solid Tumors

Duality Biotherapeutics Inc., in partnership with Avenzo Therapeutics, Inc., has initiated a Phase 1/2 clinical study to evaluate a novel EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418/DB-1418, in patients with advanced solid tumors. The first patient has been dosed in the Phase 1 segment of this trial, which aims to assess the safety, tolerability, and preliminary clinical activity of the drug both as a single agent and in combination therapy. The study is open-label and marks the first-in-human trial for this potential best-in-class therapy. Results from this study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN26675) on July 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2550650646?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550650646","market":"nz","top_or_hot":-1,"title":"Duality Biotherapeutics Inc. Initiates Phase 1/2 Clinical Trial of Innovative EGFR/HER3 Bispecific Antibody-Drug Conjugate for Advanced Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Duality Biotherapeutics Inc. Initiates Phase 1/2 Clinical Trial of Innovative EGFR/HER3 Bispecific Antibody-Drug Conjugate for Advanced Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Duality Biotherapeutics Inc., in partnership with Avenzo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc., has initiated a Phase 1/2 clinical study to evaluate a novel EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418/DB-1418, in patients with advanced solid tumors. The first patient has been dosed in the Phase 1 segment of this trial, which aims to assess the safety, tolerability, and preliminary clinical activity of the drug both as a single agent and in combination therapy. The study is open-label and marks the first-in-human trial for this potential best-in-class therapy. Results from this study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN26675) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Duality Biotherapeutics Inc. Initiates Phase 1/2 Clinical Trial of Innovative EGFR/HER3 Bispecific Antibody-Drug Conjugate for Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDuality Biotherapeutics Inc. Initiates Phase 1/2 Clinical Trial of Innovative EGFR/HER3 Bispecific Antibody-Drug Conjugate for Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-09 11:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Duality Biotherapeutics Inc. Initiates Phase 1/2 Clinical Trial of Innovative EGFR/HER3 Bispecific Antibody-Drug Conjugate for Advanced Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Duality Biotherapeutics Inc., in partnership with Avenzo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc., has initiated a Phase 1/2 clinical study to evaluate a novel EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418/DB-1418, in patients with advanced solid tumors. The first patient has been dosed in the Phase 1 segment of this trial, which aims to assess the safety, tolerability, and preliminary clinical activity of the drug both as a single agent and in combination therapy. The study is open-label and marks the first-in-human trial for this potential best-in-class therapy. Results from this study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN26675) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL2FpWBt:1","article_id":"2550650646","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550650646","pubTimestamp":1752030893,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Duality Biotherapeutics Inc. Initiates Phase 1/2 Clinical Trial of Innovative EGFR/HER3 Bispecific Antibody-Drug Conjugate for Advanced Solid Tumors. Duality Biotherapeutics Inc., in partnership with Avenzo Therapeutics, Inc., has initiated a Phase 1/2 clinical study to evaluate a novel EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418/DB-1418, in patients with advanced solid tumors. The first patient has been dosed in the Phase 1 segment of this trial, which aims to assess the safety, tolerability, and preliminary clinical activity of the drug both as a single agent and in combination therapy. The study is open-label and marks the first-in-human trial for this potential best-in-class therapy. Results from this study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B","BK1161":"生物科技"},"translate_title":"Duality Biotherapeutics Inc.启动用于晚期实体瘤的创新EGFR/HER3双特异性抗体-药物偶联物1/2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":0.9},"content_text":"Duality Biotherapeutics Inc. Initiates Phase 1/2 Clinical Trial of Innovative EGFR/HER3 Bispecific Antibody-Drug Conjugate for Advanced Solid Tumors\n    \n\n        Duality Biotherapeutics Inc., in partnership with Avenzo Therapeutics, Inc., has initiated a Phase 1/2 clinical study to evaluate a novel EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418/DB-1418, in patients with advanced solid tumors. The first patient has been dosed in the Phase 1 segment of this trial, which aims to assess the safety, tolerability, and preliminary clinical activity of the drug both as a single agent and in combination therapy. The study is open-label and marks the first-in-human trial for this potential best-in-class therapy. Results from this study have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN26675) on July 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550650646","isCrawlerRequest":true}